Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.64 |
| ▸ | PTH1R | Q03431 | 10/20 | 0.64 |
| ▸ | IL23R | Q5VWK5 | 4/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | GHSR | Q92847 | 2/20 | 0.56 |
| ▸ | NPY2R | P49146 | 1/20 | 0.56 |
| ▸ | CCKBR | P32239 | 1/20 | 0.55 |
| ▸ | GLP1R | P43220 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Penetratin SCHEMBL29356568 | 0.97 | PTH1R (0.66) | KEAP1PTH1RIL23RRXFP1GHSR | |
| SCHEMBL31749000 | 0.95 | PTH1R (0.63) | KEAP1PTH1RIL23RRXFP1GHSR | |
| SCHEMBL29710643 | 0.94 | PTH1R (0.65) | KEAP1PTH1RIL23RRXFP1GHSR | |
| SCHEMBL29350300 | 0.94 | PTH1R (0.64) | KEAP1PTH1RIL23RRXFP1GHSR | |
| SCHEMBL29429587 | 0.94 | PTH1R (0.64) | KEAP1PTH1RIL23RRXFP1GHSR | |
| SCHEMBL30299196 | 0.93 | PTH1R (0.67) | KEAP1PTH1RIL23RRXFP1GHSR | |
| Kqikiwfqnkkmkwkk-Nh2 SCHEMBL31748869 | 0.93 | PTH1R (0.60) | KEAP1PTH1RIL23RRXFP1GHSR | |
| SCHEMBL30617122 | 0.91 | PTH1R (0.61) | KEAP1PTH1RIL23RGHSRNPY2R | |
| SCHEMBL31232534 | 0.91 | PTH1R (0.68) | KEAP1PTH1RIL23RRXFP1CCKBR | |
| SCHEMBL30002139 | 0.91 | PTH1R (0.63) | KEAP1PTH1RIL23RRXFP1CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122031716-A | Carbon microsphere delivery carrier with controllable size in large range and preparation method and application thereof | 广州墨羲科技有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-20250228965-A1 | NANOPARTICLES COMPRISING AT LEAST ONE METAL SALT AND AT LEAST ONE PEPTIDE | CENTRE NAT RECH SCIENT (FR) | 2025-07-17 | — | — | US | claimed |
| US-20250114464-A1 | PRE-MRNA SLICE MODULATING PEPTIDE-CONJUGATED ANTISENSE THERAPEUTICS FOR THE TREATMENT OF DISEASES | UNIV ALBERTA (CA) | 2025-04-10 | — | — | US | claimed |
| US-20250092120-A1 | ANTICANCER PEPTIDE AND USE IN TREATING CANCER | A.T. STILL UNIVERSITY | 2025-03-20 | — | — | US | claimed |
| US-20240254179-A1 | Targeting Nuclear Speckles and DNA Speckle Association | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2024-08-01 | — | — | US | claimed |
| EP-4401710-A2 | NANOPARTICLES COMPRISING AT LEAST ONE METAL SALT AND AT LEAST ONE PEPTIDE | Centre National de la Recherche Scientifique CNRS (FR) | 2024-07-24 | — | — | EP | claimed |
| CN-118304261-A | Electric response nano-particle for epilepsy treatment or diagnosis and preparation method and application thereof | 国家纳米科学中心 | 2024-07-09 | — | — | CN | claimed |
| WO-2024078534-A1 | INTERFERING RNA FOR INHIBITING EXPRESSION OF MELANOPHILIN (MLPH) GENE, AND APPLICATION THEREOF | 北京键凯科技股份有限公司 | 2024-04-18 | — | — | WO | claimed |
| WO-2024054991-A1 | DIMERIC POLYPEPTIDE ANTAGONISTS OF THE NA/K-ATPASE-SRC RECEPTOR COMPLEX AND RELATED METHODS | MARSHALL UNIVERSITY RESEARCH CORPORATION (US) | 2024-03-14 | — | — | WO | claimed |
| WO-2023041639-A2 | HYBRID NANOPARTICLES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-03-23 | — | — | WO | claimed |
| US-20260139254-A1 | INTERFERING RNA FOR INHIBITING TOP1 GENE EXPRESSION AND USE THEREOF | JENKEM TECH CO LTD BEIJING (CN) | 2026-05-21 | — | — | US | disclosed |
| US-20260137791-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR PD-L1 | Bicyclerd Limited (GB) | 2026-05-21 | — | — | US | disclosed |
| US-12630588-B2 | Bicyclic peptide ligands specific for CD137 | BICYCLETX LIMITED (GB) | 2026-05-19 | — | — | US | disclosed |
| CN-122031716-A | Carbon microsphere delivery carrier with controllable size in large range and preparation method and application thereof | 广州墨羲科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260124312-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLETX LIMITED (GB) | 2026-05-07 | — | — | US | disclosed |
| US-20220072140-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | Bicyclerd Limited (GB) | 2022-03-10 | — | — | US | disclosed |
| WO-2022050419-A1 | QUALITY IMPROVING AGENT FOR IPS CELLS, METHOD OF PRODUCING IPS CELLS, IPS CELLS, AND COMPOSITION FOR PRODUCING IPS CELLS | Ｈｅａｒｔｓｅｅｄ株式会社 | 2022-03-10 | — | — | WO | disclosed |
| CN-114144424-A | Modified BCL9 mimetics | 智慧疗法有限公司 | 2022-03-04 | — | — | CN | disclosed |
| US-20220064221-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR INTEGRIN ALPHA-V-BETA-3 | BICYCLETX LIMITED (GB) | 2022-03-03 | — | — | US | disclosed |
| EP-3955967-A1 | PEPTIDES AND NANOPARTICLES FOR INTRACELLULAR DELIVERY OF MOLECULES | Aadigen, LLC (US) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630588-B2 | Bicyclic peptide ligands specific for CD137 | PTMS, IL36G, HLA-A | KEAP1 4214/4885PTH1R 1663/4885IL23R 79/4885 |
| US-20220064221-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR INTEGRIN ALPHA-V-BETA-3 | ITGB3, ITGAV, ITGB1 | KEAP1 3601/4885PTH1R 973/4885IL23R 691/4885 |
| US-20220072140-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | MMEL1, MMP3, TIMP3 | KEAP1 1245/4885PTH1R 2466/4885IL23R 878/4885 |
| US-20260124312-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | EPHA2, EPHB2, ERBB2 | KEAP1 1704/4885PTH1R 1213/4885IL23R 1028/4885 |
| US-20260137791-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR PD-L1 | PDCD1LG2, CD274, PDCD1 | KEAP1 1129/4885PTH1R 1368/4885IL23R 866/4885 |
| US-20260139254-A1 | INTERFERING RNA FOR INHIBITING TOP1 GENE EXPRESSION AND USE THEREOF | TOP1, TOP2A, TOP2B | KEAP1 1542/4885PTH1R 4757/4885IL23R 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.